Irban

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Irban

The following summary provides an essential overview of the identity and general purpose of the prescription drug Irban, based on the active compound Irbesartan.

Property Description
Active ingredient Irbesartan
Form Oral tablets (Film-coated)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Lowering high blood pressure
Origin Synthetic (Nonpeptide tetrazole derivative)

What Type of Medicine is Irban?

Irban is a prescription-only medicine whose active ingredient is Irbesartan, a chemically synthetic compound. This drug belongs to the Angiotensin II Receptor Blocker (ARB) class, which works specifically within the body's renin-angiotensin system. Irbesartan is recognized as an angiotensin II receptor antagonist used to manage high blood pressure. The ARB class is clinically recognized for providing effective management of elevated blood pressure while offering a different side effect profile compared to older classes like ACE inhibitors.


Composition and Physical Form of Irban

The medication is formulated around its single active ingredient, Irbesartan, and is supplied as an oral dosage form, specifically film-coated tablets intended for systemic use. Irbesartan itself is a biphenylyltetrazole derivative. These tablets are generally composed of the active compound plus pharmaceutical excipients. While Irban is available in this single-ingredient form (monotherapy), combination products containing Irbesartan plus another agent (such as a diuretic) also exist, a formulation strategy used to simplify treatment regimens.


What is the General Purpose of Irban?

The general purpose of Irban is to help lower and manage elevated blood pressure by promoting vascular smooth muscle relaxation. It achieves this by selectively blocking a natural signal that otherwise instructs blood vessels to narrow. By interrupting this mechanism, Irban allows vessels to widen, which reduces the resistance against which the heart must pump. ARBs selectively inhibit the binding of Angiotensin II, leading to vasodilation and decreased blood pressure. In simple terms, Irban makes it easier for the heart to move blood throughout the body, making it a typical treatment for individuals needing long-term cardiovascular support.

What side effects are possible with Irban?

The possible side effects and safety profile of Irban (Irbesartan) are derived from organized clinical data and post-marketing surveillance, as documented by regulatory bodies.

Adverse Reaction Categories

Side effects are classified by frequency, with Common reactions (occurring in 1/100 to < 1/10 patients) including general symptoms such as headache, dizziness, fatigue, nausea, vomiting, diarrhoea, and musculoskeletal pain. Uncommon reactions (1/1000 to < 1/100) include cough, flushing, and tachycardia.

Adverse effects are also categorized by the body system affected, known as System-Organ-Classes (SOC). Reactions are noted across the Nervous System (dizziness), Gastrointestinal Disorders (diarrhoea, dyspepsia), and Metabolic and Nutritional Disorders (hyperkalemia).

Serious Adverse Reactions and Key Safety Constraints

Official labeling highlights several serious or clinically significant events and limitations:

  • Fetal Toxicity: Irbesartan carries a regulatory Boxed Warning regarding the risk of injury and death to the developing fetus, and is contraindicated during the second and third trimesters of pregnancy.
  • Acute Reactions: Serious, rare post-marketing events include Angioedema (swelling of the face, lips, and throat) and documented cases of Acute Renal Failure.
  • Hypotension and Hyperkalemia: Symptomatic hypotension may occur at the initiation of treatment, particularly in volume- or salt-depleted individuals. The risk of hyperkalemia (elevated potassium) is officially noted, with increased incidence in patients with Type 2 diabetes and nephropathy.

Population-Specific Safety Statements

Safety-related restrictions include contraindication for co-administration with aliskiren in patients with diabetes mellitus or moderate to severe renal impairment. Furthermore, the official documents state that patients with certain pre-existing conditions, such as renal artery stenosis or severe heart failure, may be at greater risk of impaired renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Irban (Irbesartan) based on an exaggeration of its expected pharmacological effect. Overexposure primarily affects the cardiovascular system, leading to symptoms and signs of severe hypotension (low blood pressure), as described in prescribing information.

Documented manifestations reported in overdose cases include dizziness and fainting. Disturbances in heart rhythm, specifically tachycardia (fast heart rate) or bradycardia (slow heart rate), have also been documented.

Required Emergency Actions

The regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if the exposed individual exhibits documented signs of a life-threatening event. These signs include collapse, seizure, trouble breathing, or if the person cannot be awakened (unconsciousness).

Management is strictly symptomatic and supportive, as official labeling confirms that no specific antidote is known for Irbesartan overdose. The focus of medical treatment is stabilizing the patient and correcting manifestations such as severe hypotension.

Therapeutic Uses of Irban

Quick Facts: Irban Uses

  • Blood Pressure: Manages elevated systemic arterial pressure (hypertension).
  • Kidney Function: Supports kidney health in patients with Type 2 diabetes and hypertension, particularly those with signs of nephropathy.

Irban (irbesartan) is a prescribed medication utilized to manage key cardiovascular and renal conditions. Its primary use is in the care of hypertension, which is sustained elevated blood pressure. Achieving and maintaining appropriate blood pressure levels is an important aspect of a health management plan.

Irban is also indicated to support the management of diabetic nephropathy in patients who have Type 2 diabetes and concurrent hypertension. In this population, Irban is employed as part of a therapeutic regimen intended to help delay the progression of kidney-related complications, such as a doubling of serum creatinine levels or the need for renal replacement therapy. This application is a standard component of its clinical indications.

Eligibility and Restrictions for Use

The use of Irban (Irbesartan) is strictly defined by official population eligibility rules, being primarily approved for adults aged 18 and older.

Absolute Contraindications

Irban is strictly contraindicated in patients with a known hypersensitivity to irbesartan or any product component. It must not be used in women during the second and third trimesters of pregnancy due to fetal risk. Furthermore, patients with diabetes or moderate-to-severe renal impairment must avoid using Irban concurrently with aliskiren-containing products.

Age and Special Populations

Use is not established in children under 6 years of age. For those aged 6 to 18 years, data is noted as insufficient to support a general recommendation for use. Irban is generally not recommended for breastfeeding women due to the potential risk to the infant, and women of childbearing potential require appropriate counseling.

Conditional Use and Restrictions

Special caution is indicated for patients with renovascular disease or those with aortic or mitral valve stenosis. Patients who are severely volume- or salt-depleted must have this condition corrected before starting treatment. While no dose adjustment is required for mild to moderate hepatic or renal impairment, regulatory documentation notes that clinical experience in severe hepatic impairment is lacking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Irban's (Irbesartan) official regulatory profile details documented interactions primarily based on pharmacodynamic and pharmacokinetic effects.

Interaction Type Interacting Agents / Products
Contraindicated Combinations Aliskiren-containing medicines are strictly prohibited in patients with diabetes mellitus or those with renal impairment (GFR less than 60 mL/min/1.73 m^2). Dual blockade of the Renin-Angiotensin System (RAAS) with an ACE inhibitor is also contraindicated in patients with diabetic kidney disease.
Pharmacodynamic Effects Co-administration with potassium-sparing diuretics (e.g., Spironolactone, Amiloride), potassium supplements, or salt substitutes containing potassium carries an increased risk of hyperkalemia. Combining Irban with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may lead to an attenuation of the antihypertensive effect and an increased risk of worsening renal function, especially in the elderly.
Exposure Modification Lithium and Irban combination is not recommended due to Irbesartan potentially reducing Lithium's clearance, which increases serum lithium concentration. CYP2C9 inhibitors (e.g., Fluconazole) may increase the systemic exposure (AUC) of Irban as it is primarily metabolized by the CYP2C9 isoenzyme.
Food/Timing Rules No clinically significant interaction with food is documented. No mandatory timing separation rules between doses are documented in regulatory labels.

The regulatory documentation establishes these interaction constraints to manage the risks associated with additive physiological effects (Dual RAAS Blockade, hyperkalemia) and altered drug concentrations (Lithium, CYP2C9 inhibitors). This structure defines which co-administrations are formally prohibited or strongly discouraged, particularly in specified patient populations.

Mechanism of Action

How Irban Works: Mechanism of Action

Irban acts by selectively modulating specific ion channels, leading to a reduction in the spontaneous firing frequency of the sinoatrial (SA) node.


The Pacemaker Current ( I f Channel) Inhibition

Irban's primary mechanism involves the targeted and specific inhibition of the I f current (funny current) within the sinoatrial (SA) node pacemaker cells. This current, mediated by HCN channels, facilitates the spontaneous diastolic depolarization—the electrical process that governs the heart's rhythm. The channel blockade decreases the slope of the depolarization, initiating a physiological cascade that results in a reduction of the heart's firing rate.


The Chronotropic Cascade

This domain describes the consequence of I f current inhibition, resulting in a reduction in heart rate (negative chronotropy) without affecting myocardial contraction (inotropy) or relaxation (lusitropy). The physiological consequence is a prolongation of the diastolic phase, which is associated with increased duration for coronary artery perfusion and ventricular filling.


Retinal I h Channel Modulation

Irban also exhibits weak, off-target modulation of the similar I h current found in the retinal photoreceptors. This interaction is a direct mechanistic consequence of the drug's activity on the HCN channel family. This molecular interference alters the retinal signaling cascade, resulting in the generation of luminous phenomena known as phosphenes.

Dosage and Administration Information

The administration of Irban (Irbesartan) follows prescribed clinical protocols to standardize its use. The medication is an oral treatment supplied as film-coated tablets in available strengths of 75 mg, 150 mg, and 300 mg. Irban is intended for chronic, long-term management of conditions. The maximum antihypertensive effects of any dose adjustment are typically observed over a period of two to four weeks, which guides the timing for dose titration.

Standardized Dosing and Schedule

Instruction Detail
Route of Administration Oral.
Dosing Frequency Once daily.
Adult Starting Dose 150 mg once daily for most adults with hypertension.
Maximum Daily Dose 300 mg.
Contextual Intake May be taken with or without food.

Use in Specific Populations

Established protocols address specific clinical contexts to ensure proper administration. Patients who are volume or salt-depleted, such as those receiving high-dose diuretics, require a reduced initial dose of 75 mg once daily, or their volume status must be corrected prior to initiation. No general dose adjustments are typically necessary for individuals with mild-to-severe renal impairment or mild-to-moderate hepatic impairment, unless volume depletion is a factor. Furthermore, the safety and effectiveness of Irbesartan have not been established for children under six years of age. These parameters collectively define the clinical protocol for Irban in therapeutic settings.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy Studies

Research examined the study drug in studies evaluating its use in individuals with chronic joint pain. In one key study, 600 participants were randomized across three groups: 100 mg/day, 200 mg/day, and placebo. The study protocol often specified the lowest dose as the initial dose tested.

  • Osteoarthritis (OA): Primary endpoints included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score and the Patient Global Assessment (PGA). Mean WOMAC pain scores demonstrated a difference between the 100 mg and 200 mg groups compared to placebo after 6 weeks.
  • Rheumatoid Arthritis (RA): RCTs reported differences in ACR20 scores associated with the 100 mg/day dosage over up to 24 weeks. The percentage of patients reaching an ACR20 response was noted to be 55% for the 100 mg group, compared to 28% for the placebo group.

Phase III trials reported results that suggested an onset of action, with changes in mobility noted within 48 hours of the first dose. Research also examined the co-administration of the drug with an immune modulator in studies focusing on severe inflammation.


Safety and Tolerability Profile

Safety data was collected from over 5,000 patient-years of exposure across all pivotal studies. Comparative studies evaluated patient tolerability and GI safety profile, noting differences in the observed incidence of GI events relative to older NSAIDs.

  • Gastrointestinal (GI) Safety: The incidence of gastric ulcers or clinically significant GI bleeds was reported as 0.5% in the 100 mg group over one year of treatment. The observed incidence was 0.5%, compared to 2.1% reported for a non-selective NSAID used in the comparative arm of the study.
  • Cardiovascular (CV) Safety: Long-term safety studies have investigated the drug's profile in cardiovascular patients. The Vioxx Gastrointestinal Outcomes Research (VIGOR) study results were analyzed to track the incidence of thrombotic CV events. Individuals with a history of MI were often excluded from or noted as a factor in the design of certain studies.
  • Adverse Events (AEs): The most frequently reported adverse events (incidence >10%) included upper respiratory tract infection, diarrhea, and headache. The severity of these events was characterized as mild-to-moderate by study investigators.

Frequently Asked Questions (FAQ)

Common questions about Irban (FAQ)

Q: How quickly does Irban usually start to work?

According to official product information, the blood pressure-lowering effect of Irban is apparent after the first dose. The effect is typically close to its full level after two weeks, with the maximum therapeutic effect usually taking about four to six weeks of consistent treatment.


Q: Do studies suggest Irban is effective for its main use?

Studies cited in regulatory documents confirmed the antihypertensive effects of Irban. These major trials, which lasted 8 to 12 weeks, showed statistically and clinically significant decreases in blood pressure when compared to a placebo.


Q: Is Irban safe to use for older adults (seniors)?

Official regulatory documents indicate that a general dosage adjustment is not typically required for older adults. However, for patients over 75 years of age, a lower initial starting dose may be considered. Efficacy and safety were generally similar between older and younger patients in clinical studies.


Q: Can Irban cause any long-term effects on the liver or kidneys?

Drugs in this class can potentially affect kidney function, and rare cases of acute renal failure have been noted. The official label states that periodic monitoring of kidney function may be necessary for patients at risk. Occasional temporary elevations of liver enzymes have also been reported.


Q: What are the ingredients in Irban besides the active substance?

Besides the active ingredient, Irbesartan, the tablets contain inactive ingredients, also known as excipients. These compounds help form the pill and typically include substances such as calcium stearate, microcrystalline cellulose, and colloidal silicon dioxide.


Q: Why is Irban sometimes prescribed for uses other than its main one?

The main approved purpose of Irban is to help lower high blood pressure (hypertension). Official indications also include the use of Irbesartan for treating renal disease in adult patients who have hypertension and Type 2 diabetes mellitus.


Q: Is it true that Irban can cause skin rashes?

Yes, a skin rash is noted in official documentation as a potential sign of a serious allergic reaction (hypersensitivity) to Irban. Patients may experience a rash that is swollen, raised, itchy, blistered, or peeling, and this is noted in official documents as a symptom that requires immediate reporting.


Q: Why do official documents list so many potential drug interactions for Irban?

Official documents list various potential interactions because Irban works by modulating the renin-angiotensin system, which is central to controlling both blood pressure and potassium levels. These warnings help ensure patients avoid combinations that could cause excessively low blood pressure or dangerously high potassium levels (hyperkalemia).


Q: What is the likelihood of a serious side effect from Irban?

According to official safety information, serious side effects from Irban, such as a severe allergic reaction (anaphylaxis) or significant problems related to potassium levels or kidney function, happen rarely.


Q: Do studies exist that compare different ways of using Irban?

Yes, studies have examined different approaches to using Irban. This includes comparisons of administration methods, such as once-daily versus twice-daily dosing, and its use alone (monotherapy) versus in combination with other blood pressure agents.


Q: Are there any long-term follow-up studies on Irban users?

Irban is intended for the chronic, long-term management of high blood pressure. While initial efficacy trials have specific end dates, the safety profile continues to be monitored through ongoing post-marketing surveillance required by regulatory bodies for all long-term medications.


Q: Can Irban affect my ability to drive or operate machinery?

Yes, the medication can cause dizziness or lightheadedness, particularly when treatment is first started. Official information indicates that activities requiring full mental alertness, such as driving or operating machinery, should be avoided until the patient is familiar with how the medication affects them.


Q: What are the common signs of an allergic reaction to Irban?

Signs of a serious allergic reaction include swelling of the face, lips, tongue, or throat (known as angioedema), or having difficulty breathing or swallowing. A rash that is swollen, raised, or severely itchy may also be a symptom.


Q: What happens if I forget to take Irban?

If you miss a dose of Irban, take it as soon as you remember. If it is almost time for your next scheduled dose, regulatory guidance typically suggests skipping the missed dose and resuming your regular schedule. Official guidance warns against taking a double dose to make up for a missed one.


Q: Can Irban be taken at the same time as my vitamins?

While no specific interaction with general vitamins is detailed in the official documents, it is important to be cautious about supplements containing potassium. Official information warns against the use of potassium supplements or salt substitutes containing potassium without consulting a healthcare provider.


Q: Is Irban the same type of medicine as [similar drug name]?

Irban's active ingredient, Irbesartan, is classified as an Angiotensin II Receptor Blocker (ARB). This type of medicine works by selectively blocking the action of a natural compound in the body, which helps to relax blood vessels and lower blood pressure.


Q: Can taking Irban affect my appetite?

Loss of appetite is not listed as a common side effect, but it is noted as a potential symptom associated with more serious adverse events. For instance, it may be linked to fluid and electrolyte problems or changes in kidney function.


Q: What is the longest time a person can safely use Irban?

Irban is officially indicated for the chronic, long-term management of high blood pressure. The drug label does not specify a maximum duration of use, as the medicine is intended to be used over an extended period.


Q: What if I'm already taking an antibiotic, is Irban still okay?

While many common antibiotics are not listed as major interactions, the combination of Irban with the antibiotic sulfamethoxazole/trimethoprim is noted to increase the risk of developing high potassium levels (hyperkalemia). It is important that healthcare providers are aware of all medications being taken.


Q: What should I do if I accidentally take more Irban than usual?

Taking more Irban than usual may lead to symptoms such as dizziness, fainting, or a change in your heartbeat (either fast or slow). Official guidance for this situation is to seek emergency medical attention immediately.


Q: Can Irban be split in half if the pill is too big?

The official product information states that the 150 mg and 300 mg tablets may be split for ease of swallowing. The labeling specifies that tablets are not intended to be split to change the dose, and that both halves of a split tablet should be taken together.


Q: How does Irban compare to generic alternatives?

The active ingredient in Irban, Irbesartan, is available as a generic product that meets the standards of the United States Pharmacopeia (USP). Regulatory requirements ensure that generic formulations contain the same active ingredient and meet the same quality and effectiveness standards as the original branded drug.


Q: Can I drink alcohol in moderation while taking Irban?

Official regulatory information indicates that alcohol may have an additive effect in lowering your blood pressure. This combination could increase the occurrence of side effects such as dizziness, lightheadedness, or fainting.


Q: How soon after stopping Irban do the effects wear off?

Clinical studies show that the blood pressure-lowering effect of Irban is long-lasting. For instance, approximately two-thirds of the drug's effect was still present one week after the last dose was taken in a study setting.


Q: What kind of monitoring or tests are needed while on Irban?

Since Irban can affect kidney function and potassium levels, regulatory information indicates that routine monitoring may be needed. This usually involves regular blood tests to check how well your kidneys are working and to track the amount of potassium in your blood.


Q: What should I do if the side effects of Irban are too difficult to handle?

If you experience any signs of a serious adverse event, such as swelling of the face or throat, or symptoms suggesting high potassium or kidney injury, seeking emergency medical attention immediately is indicated in these circumstances. These events are noted in official documents as serious, though rare, side effects.


Q: Are there specific patient groups that respond best to Irban?

In clinical studies, patients showed generally similar blood pressure responses regardless of sex or age (over and under 65 years). However, the blood pressure-lowering effect was noted to be somewhat less pronounced in the black hypertensive population compared to other groups.


Q: Can stress or illness affect how well Irban works?

Illnesses that cause fluid loss, such as those with severe diarrhea, vomiting, or excessive sweating, can lead to a state of volume or salt depletion in the body. This condition may cause a significant or excessive drop in blood pressure, requiring careful monitoring.


Q: Are there any known interactions between Irban and herbal supplements?

Official documents do not typically list specific herbal interactions, but they advise patients to inform their healthcare providers about all other medications, vitamins, and herbs they use. This allows for necessary monitoring to ensure safe use.


Q: Does Irban cause weight gain or weight loss?

Weight change is not listed as a common side effect. However, a rapid weight gain may be a sign of a serious adverse event, such as a kidney problem potentially causing fluid retention, and this is noted as an event that should be reported to a healthcare professional immediately.


Q: Is Irban a narcotic or controlled substance?

Official regulatory classification confirms that Irban (Irbesartan) is a Human Prescription Drug and is not listed on the DEA Schedule. This means it is not considered a federally controlled substance or narcotic.


Q: Can I stop taking Irban suddenly if I feel better?

Official information indicates that patients should continue taking Irban for long-term management and should avoid stopping the medication without consulting a healthcare professional. The medication is intended for long-term management to maintain proper blood pressure control.


Q: Can Irban affect my blood sugar levels?

Irban is specifically contraindicated for use with a medicine called aliskiren in patients who have diabetes mellitus. However, in some clinical studies of Irban used alone, the medicine did not show a significant effect on patients' blood sugar (glucose) or HbA1 c levels.

How should Irban be stored and disposed of?

How to Store and Dispose of Irban (Irbesartan)

Irban tablets must be stored according to official regulatory conditions to maintain product stability and quality. The medication must be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with protection from excess heat, light, and moisture. It is required to keep the tablets in the original container, tightly closed, and they must not be frozen.

Protection and Stability

Storage Constraint Requirement
Temperature Store between 20 C and 25 C.
Protection Keep away from light, moisture, and do not freeze.
Child Safety Store out of the reach and sight of children.
Stability Note Do not use the medicine after the labeled expiry date.

Disposal

Unused or expired Irban must be disposed of properly. Do not discard the medication with household garbage or flush it down the toilet or drain. Disposal must be conducted according to local, regional, and national regulations, often through authorized take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Irban found in:

A-Z Index: